https://doi.org/10.62585/sigh.v1i2.87



Volume and Issues Obtainable at Centeriir.org
Journal of Social Informatics and Global Health
ISSN (Print): 3006-9424 ISSN (Online): 3006-9432

Volume 2, No.1, 2023
Journal Homepage: https://journals.centeriir.org/index.php/sigh

The Ripple Effect of Vaccines: Health, Economic, and Social Dimensions

Aalam Khan Thaheem[1] **Ali Umar Qureshi**[2] **Amitabha Sarkar**[3] **Gaungqi Liu**[4]

[1]Research Fellow, Nanjing University, China. E-Mail:aalam_azad@hotmail.com
[2]Research Fellow, Department of Management Information, University of Malaya, Malaysia. E-Mail: aliumar7666@gmail.com
[3]Center of Social Medicine and Community Health, Jawaharlal Nehru University, New Delhi, India.
E-Mail: Amitsarkarmedi6@live.com
[4]Department of Global Health, School of Public Health, Peking University, Beijing, China. E-Mail: Gaungqilue345@gmail.com

ABSTRACT

This study assesses the critical impact of vaccines on global health and population growth, citing a WHO 2018 report that emphasizes their role in dramatically reducing mortality. It explores the challenge of ensuring equitable vaccine access, particularly under constraints like remote locations and socio-political instability. The research highlights the integral roles of organizations such as WHO, UNICEF, and Gavi in facilitating vaccine distribution, especially evident during the COVID-19 pandemic. By examining the broader economic and social benefits of vaccines, this study advocates for informed policy-making to enhance vaccine funding and accessibility. The aim is to underscore the need for ongoing international cooperation to overcome the remaining barriers to global vaccine coverage.

Article History: Received: September 02, 2023: Accepted: October 02, 2023: Published: October 05, 2023
Keywords: vaccine, health, who, covid 19

Corresponding Author's E-Mail: aalam_azad@hotmail.com

https://doi.org/10.62585/sigh.v1i2.87

1. Introduction

The transformative role of vaccination in enhancing global well-being is monumental. As reported by the World Health Organization (WHO) in 2018, apart from clean water access, no other intervention has more significantly reduced mortality and fueled population growth. The development of vaccines that are both safe and effective against major diseases represents a cornerstone achievement of the 21st century. Together with sanitation and clean drinking water, vaccines are part of a vital triad of public health measures that have dramatically improved health outcomes across the globe.

Each year, vaccinations prevent an estimated 6 million deaths from vaccine-preventable diseases, affirming their critical role in global health strategies (WHO, 2018). Additionally, projections by Vollet et al. (2020) suggest that, "the global population will reach approximately 10 billion by 2055, a growth partly attributed to the life-extending benefits of widespread immunization."

Despite these advances, considerable challenges remain in ensuring equitable access to vaccines, particularly for populations in remote areas, those skeptical of vaccine efficacy, and those in regions affected by conflict. In this context, As noted by Pagliusi et al. (2019), "Organizations like the World Health Organization (WHO), United Nations Children's Fund (UNICEF), Gavi, the Vaccine Alliance, The Bill & Melinda Gates Foundation, and the Coalition for Epidemic Preparedness Initiatives (CEPI) play indispensable roles." These organizations, with their diverse funding mechanisms, have been pivotal in expanding the reach of vaccines globally.

The importance of these collaborative efforts was starkly highlighted during the global pandemic of SARS-CoV-2 in 2019, which underscored the profound health and economic impacts of COVID-19 across societies in high-, middle-, and low-income countries. This study aims to elucidate the comprehensive benefits of vaccination on societal health, economic stability, and social cohesion. It will argue that these dimensions are critical for policymakers to consider when evaluating the overall impact of vaccines and deciding on their funding priorities.

2. The Evolution of Vaccination: A Historical Overview

Documented efforts to thwart specific diseases trace back to 1500 AD in China, where the technique of variolation was used against smallpox. This early method involved embedding material from smallpox scabs into the skin to induce immunity. By 1796 in the United Kingdom, Edward Jenner observed that milkmaids who contracted cowpox did not catch smallpox. He hypothesized that injecting material from cowpox sores, likely containing a virus akin to vaccinia, could render people immune to smallpox. This led to the development of the first smallpox vaccine in 1798 (Little, 2021). Significant advancements were not seen until nearly a hundred years later, with progress in manipulating pathogens to isolate effective vaccine antigens. In the late 19th and early 20th centuries, Louis Pasteur's experiments with oxygen and heat paved the way for the creation of live-attenuated vaccines against chicken cholera and rabies, as well as an inactivated vaccine for anthrax. Further developments included the live "Bacille Calmette-Guerin (BCG) vaccine," employed against tuberculosis, which was developed through techniques such as the repeated culturing of Mycobacterium bovis (Lange et al., 2022). Similar serial passage methods were used to develop vaccines for yellow fever using chicken embryo tissues.

The late 19th century also saw the development of whole-cell inactivated bacterial vaccines, utilizing heat and chemical methods to kill and deactivate pathogens. This led to the production of vaccines for diseases like typhoid, cholera, and pertussis. In 1923, Alexander Glenny and Barbara Hopkins introduced methods for neutralizing bacterial toxins with formaldehyde, culminating in the creation of diphtheria and tetanus toxoid vaccines.

Progress in in vitro virus culture facilitated the in-depth study of viral pathogens, and the growth of these pathogens in artificial circumstances resulted in the development of live oral vaccinations for polio, measles, rubella, mumps, and varicella viruses. As highlighted by Artenstein, (2021), "In the 1960s at the "Walter Reed Army Institute of Research," vaccines were created utilizing capsular polysaccharides, including encapsulated organisms including meningococci and subsequently pneumococci and Haemophilus influenzae type b (Hib) Polyvalent vaccinations were created to protect several serotype variations of polysaccharide capsules." These vaccines were then combined

with carrier proteins to increase their effectiveness, especially in babies. This was achieved by stimulating T-cell mediated assistance to generate memory B-cells. vaccinations composed only of proteins were uncommon, save for toxoid vaccinations. However, a specific kind of vaccine called the acellular pertussis vaccine, which contains five protein antigens, was created to reduce the adverse effects associated with the entire cell vaccine.

At the close of the 20th century, there was a significant breakthrough in molecular biology that led to advancements in microbiology and immunology. This breakthrough offered valuable knowledge about pathogen epitopes and how the body responds to vaccination. The advancement of molecular genetics and genome sequencing has facilitated the creation of vaccinations targeting RNA viruses that have many versions of epitopes. Examples of such vaccines are live and inactivated influenza vaccines and live rotavirus vaccines (Graham, 2013). As highlighted by Chen et al., (2022), "The alteration and removal of DNA enabled the use of surface antigen as hepatitis B viral vectors. The immunogenicity of the human papilloma virus (HPV) vaccine is improved by the creation of virus-like particles via the L1 antigen of each virus included in the vaccination. The process of sequencing bacterial genomes has allowed for a thorough examination of meningococcal antigens, with the aim of identifying proteins that might be used in the development of meningococcal B vaccines."

In 2020, the creation of a vaccine was tried in response to the emergence of a new coronavirus called SARS-CoV-2. This virus originated in China and caused widespread respiratory sickness with severe symptoms. Within a span of 5 months between the identification of this virus on January 7, 2020 and the confirmation of person-to-person transmission (Chan et al., 2020), a total of 5,697,334 cases have been reported. The true scale of the outbreak is likely far larger, and almost no nation has been unaffected by the pandemic.

As mentioned by Bhutia et al., (2021), "As a result of earlier advancements in the study of vaccines, 73 potential vaccines were being studied in the pre-clinical phase of inquiry. By, 2020, there were six studies in Phase 1 or 1/2 and one study in Phase 2/3. The promptness of this reaction showcased the capacity to use current technologies such as RNA vaccine platforms (NCT04283461), DNA vaccine platforms (NCT04336410), recombinant vector vaccines (NCT04313127, NCT04324606), and adjuvants."

Due to the pressing global public health necessity, the rapid authorization, production, and dissemination of vaccines will be crucial, drastically shortening the typical development timeline from years to mere months. While the efficacy and broader health outcomes of these vaccines are yet to be fully confirmed, should they prove effective, it is essential that access to these vaccines is extended globally to regions affected by SARS-CoV-2. Financing these efforts will be complex amidst the constraints of national economic and social restrictions and widespread state borrowing. Nevertheless, the justification for such investment lies in the substantial societal benefits anticipated, as a healthy populace is essential to rejuvenate economies in the aftermath of COVID-19. To grasp the comprehensive history of vaccination, it is important to consider the public health initiatives that have facilitated the extensive deployment of vaccines globally. Initiated by the (WHO) in 1974, the Expanded Program of Immunization (EPI) aimed to guarantee routine vaccination for all children by 1990. By 1977, international protocols were put into place to advance vaccination efforts against diseases such as, "diphtheria, pertussis, tetanus, measles, polio, and tuberculosis" (Uwizihiwe et al., 2015). Over the years, the EPI has been expanded to include immunizations against hepatitis B, Hib, and pneumococcal diseases in various territories. By 2017, vaccination coverage for diphtheria, pertussis, tetanus, and measles had reached 85% among children aged 12-23 months worldwide, indicating significant progress in public health vaccination strategies.

3. Health Benefits of Vaccines: Reducing Disease Morbidity and Mortality

Vaccines have had a major effect on reducing illness and death caused by severe diseases, particularly in youngsters. Vaccines are projected to save around "six million deaths per year and preserve 386 million life years and 96 million disability-adjusted life years (DALYs) worldwide" (Li et al., 2019). The conventional metrics for assessing the impact of vaccines are vaccine efficacy, which measures the level of protection provided to a vaccinated group in ideal conditions such as clinical trials, and

vaccine effectiveness, which evaluates the direct and indirect effects of vaccines on the general population in real-world scenarios. Quantifying the vaccine's effect requires evaluating the degree to which it prevents illness and death. As highlighted by Younger (2016), "that in the United States in 2009, the vaccination of an annual birth cohort against 13 illnesses averted over 20 million instances of sickness and 42,000 fatalities." By 2017, the incidence of infectious illnesses that caused significant death and morbidity in the early 20th century in the United States had decreased by more than 90%. Since the number of cases was highest before the vaccine was available, there has been a significant decrease in cases owing to a high percentage of people receiving the DTaP (diphtheria, tetanus, and acellular pertussis), MMR (measles, mumps, and rubella), and polio vaccinations. Other high-income nations also had a comparable decline in infectious illnesses, which indicates the effectiveness of vaccines when they are both accessible and available.

On a global scale, the distribution of vaccinations is more difficult in many low- and middle-income countries (LMIC). This is evident from the fact that the EPI vaccines were not made accessible to every kid by 1990, regardless of the location. The main obstacle to vaccine introduction is the limited availability of financial resources (Lindstrand et al 2021). However, other barriers also contribute to this issue. These include a lack of understanding of the importance of vaccines at the local and regional levels due to insufficient data on disease burden, vaccine effectiveness, and cost-effectiveness. Additionally, there is inadequate healthcare infrastructure for the proper handling, storage, and management of vaccines, as well as for disease surveillance. Furthermore, there is a lack of global, regional, or local policy-making and leadership in this area. In 2018, as mentioned by Rodrigues et al., (2018), "the worldwide adoption of three doses of DTaP vaccine reached 86%, representing a total of 116,300,000 newborns. The vaccination coverage varies across low-, middle-, and high-income nations due to a mix of economic and political factors, as well as varying access to non-governmental funding from Gavi, the vaccination Alliance." However, there has been a reduction in the worldwide impact of illnesses caused by microorganisms that may be prevented by vaccines, resulting in improved health for millions of children. Another advantage of vaccination is the evidence that, although vaccinations may not always completely prevent an infection, such as with VZV or pertussis, they may lead to a less severe illness course.

4. Eradication of Infectious Diseases

Eradication of infectious diseases is achievable for pathogens confined to human hosts. Achieving this requires high immunity levels worldwide to halt the transmission of diseases in our globally connected community. Additionally, precise and reliable diagnostic tests are essential for ongoing case monitoring, and robust surveillance systems must be established to observe disease regression. To date, smallpox is the only human disease successfully eradicated through vaccination. Historical records trace smallpox back to Egyptian mummies from 1000 BC. The World Health Assembly announced in 1980 that the eradication of smallpox was achieved through ring vaccination, a strategy based on Edward Jenner's pioneering use of the vaccinia virus, marking a significant milestone in public health (Senti et al., 2018).

Another eradication success story is that of the rinderpest virus in livestock, which was responsible for widespread agricultural devastation and resultant humanitarian crises through malnutrition and poverty, leading to loss of human lives. In the nineteenth century, rinderpest affected cattle, bison, and various other domestic animals, causing extensive outbreaks across Africa and Europe. The Plowright tissue culture rinderpest vaccine, developed in the 1950s, played a crucial role in the global vaccination efforts that led to its eradication in 2011 (Gonzalez & Macgregor-Skinner, 2022).

The eradication of the wild poliovirus is currently a global priority. Before the advent of vaccines, polio, known for causing paralysis, impacted children and adults in both affluent and less-developed regions. As mentioned by Kraan et al., (2014), "The development of the inactivated polio vaccine (IPV) in 1955 and the live-attenuated oral polio vaccine (OPV) in 1963 marked significant advancements, with both vaccines targeting all three types of the wild polio virus." Despite the OPV being more cost-effective and easier to administer, it carries the risk of evolving into a circulating vaccine-derived poliovirus (cVDPV) through mutation and regaining neurovirulence. Therefore,

because of its high level of safety, IPV was favored in industrialized areas and places with a low frequency of polio. As mentioned by Cochi et al., (2014), “The Global Polio Eradication Initiative, launched in 1998, is a prominent public-private partnership led by national governments in collaboration with the WHO, Rotary International, United States Centers for Disease Control and Prevention (CDC), and UNICEF. Its primary objective is to eradicate polio worldwide by the year 2000.” Even though the aim was not achieved owing to insufficient financing, political determination, and the presence of other health efforts, there was a significant 99% decrease in the occurrence of polio by the year 2000. By 2003, there were only six nations where new instances of the disease were found exclusively: Egypt, Niger, India, Nigeria, Afghanistan, and Pakistan. However, by 2005, only the last four countries still had new cases. The eradication efforts in India faced challenges owing to the combination of high birth rates, inadequate sanitation, densely populated areas with underprivileged groups, and significant population movement. In 2014, India was officially proclaimed free from the poliovirus.

In 2015, eradication efforts successfully eliminated wild poliovirus type 2, while the last known case of wild type 3 occurred in 2012, leading to its formal eradication declaration in 2019. Presently, wild type 1 poliovirus persists only in Pakistan and Afghanistan. In a significant achievement, Nigeria marked three years without a reported case of polio in 2019, thus becoming the final African country to stop the disease's spread. During the initial half of 2020, Pakistan and Afghanistan reported 51 and 17 cases of wild type 1 polio, respectively (Zaffran et al., 2018). Efforts to implement comprehensive immunization programs in these countries are hindered by challenges such as armed conflicts, political instability, remoteness of regions, and inadequate infrastructure. Another major challenge in eradicating polio is the transmission of vaccine-derived paralytic poliomyelitis through the fecal-oral route, which has led to outbreaks. This situation requires vigilant surveillance to manage and mitigate the risk of OPV recipients developing cVDPV-related conditions.

5. Economic Benefits

The interplay between health and the economy is inherently reciprocal: economic advancements facilitate health-enhancing investments, and conversely, a healthy populace positively impacts and strengthens the economy. Vaccinations, along with other public health measures like sanitation, access to clean water, and pharmaceuticals, provide not only social benefits but also substantial economic gains. A broader evaluation of the economic impact of vaccines is recommended, taking into account more than just the direct healthcare savings from preventing illnesses and the related costs of caregiving. Brazier et al., (2017) developed a methodology to measure the broader economic benefits, including productivity gains related to health outcomes, secondary public health effects, risk mitigation, and health improvements.

Research indicates that children in good physical health tend to perform better intellectually, which can be attributed to their higher school attendance rates and better performance on cognitive assessments. This link has been supported by numerous studies, including those conducted by Barham. Additionally, specific educational interventions might be needed to address sensory impairments such as hearing loss from mumps, rubella, or pneumococcal infections, and vision problems caused by measles. There may also be a need for significant interventions to address the cognitive deficits associated with these childhood diseases (Fernandez, 2022).As the number of children who live to maturity continues to rise, there is a growing population of individuals who can participate in the labor force. When these folks are in a state of optimal health, they are capable of engaging in work for extended durations and exhibit enhanced physical and cognitive productivity. It is worth mentioning that this finding mostly pertains to gains in general health, rather than being directly attributed to vaccination (Drigas & Mitsea, 2020). Vaccination has been shown to result in reduced fertility rates and a fall in the number of families in civilizations that are both healthy and economically wealthy. Improved health and longer lifespan have a wider influence on families, perhaps prompting them to invest more resources towards their future goals, such as enhancing schooling or augmenting savings. Overall, vaccination activities should be seen as a strategic investment in the growth and efficiency of people, leading to enduring impacts on economies worldwide.

6. Impact of Life Expectancy and Opportunity

Vaccination programs enhance social mobility by mitigating the impact of poverty, as well as the consequent adverse health effects and mortality arising from infectious diseases, on an individual's life prospects. Multiple studies have shown that individuals who get vaccines, especially babies and children, have the potential to have a longer lifespan. It is increasingly acknowledged that as individuals become older, they undergo immunosenescence, which is the term used to describe the decrease in immune system functionality (Santoro, Bientinesi & Monti, 2021). This decrease results in a higher frequency and greater intensity of infectious diseases. Consequently, in several nations, elderly persons are administered immunizations as a preventive measure against diseases with significant mortality and morbidity rate. The vaccinations mentioned include influenza, pneumococcal, herpes zoster, and pertussis vaccines. These procedures successfully prevent the development of pneumonia, hospitalization, and the resulting risks of death from heart failure, as shown by observations in Sweden.

In the 21st century, the interconnectedness of the world provides opportunities to investigate alien civilizations, ecosystems, and the microbes that reside inside them. The accessibility of immunizations that provide defense against foreign infections has greatly enhanced the security of global travel (Upreti, 2023). Individuals may engage in migration out of need as a result of armed conflict and hostilities, in order to seek better opportunities for their lives, or for leisurely pursuits. Vaccines are crucial in aiding and alleviating the difficulties faced by refugees during mass migrations. They effectively tackle the considerable obstacles presented by illnesses such as measles and cholera in refugee camps. As mentioned by Yazli et al., (2016), “Significant global cultural or religious gatherings, such as the Hajj pilgrimage or the Chinese New Year, have been associated with the spread of meningococcal disease outbreaks. Pre-travel vaccines provide optimal protection for those who have scheduled excursions, including immunity against yellow fever, hepatitis A and B, rabies, Japanese encephalitis, tick-borne encephalitis, typhoid, and cholera.”

7. Advancing Women's Empowerment

Vaccination programs are both influenced by and contribute to the empowerment of women. The level of education, literacy, and autonomy of girls and women varies significantly worldwide and within individual nations. Improved childhood vaccination rates are seen when women possess the necessary knowledge and autonomy to make health-related decisions for their children. A study conducted in rural Bihar State, India, examined the impact of an empowerment program on women's knowledge of health and hygiene (Seidu et al., 2023). The study found that the children of women who participated in the program had a higher vaccination rate for DTP, measles, and BCG compared to children whose mothers did not participate in the program (Besnier, 2022). In addition, the provision of this knowledge and autonomy resulted in enhanced vaccination rates for children whose parents did not participate in the program, in comparison to communities that did not implement the education program. This improvement was achieved via the use of social or formal continuing conversation within the village community. From 2005 to 2012, a distinct public health campaign was carried out in Haryana, India to diminish disparities in maternal and child health (Das et al., 2021). This program focused on enhancing the availability and delivery of healthcare services to rural regions, economically disadvantaged individuals, as well as mothers and children. An important result of this campaign was the fair distribution of vaccines to both girls and boys, even though there was a previous bias towards males before the public health initiative began. Enhancing the rates of survival among infants and children from infectious diseases would result in a higher number of children reaching maturity, hence increasing their prospects of leading fruitful and healthy lives. As a result, women who are in good health and financially stable have fewer children and experience lower rates of illness and death after childbirth. Consequently, women can allocate more time towards nurturing their children and facilitating their growth, while also focusing on their education and making valuable contributions to the labor market (Doku et al., 2020). The efficacy of maternal immunization in avoiding infections like as pertussis, influenza, and tetanus in newborns who are not yet eligible

for vaccination is very successful. Women's uptake of maternal immunization is influenced by factors such as their prior experiences with healthcare and vaccinations. Therefore, it is essential to ensure that they have the necessary access and support to make educated decisions throughout their pregnancy.

8. CONCLUSION

The influence of vaccinations on society is profound and multifaceted, yet these impacts are not always easily quantifiable or widely communicated. Traditionally, vaccines have been developed primarily to reduce the incidence and mortality of infectious diseases, a focus that continues to drive much of the vaccine research and development, particularly in response to emerging outbreaks and for the protection of vulnerable groups. However, there is an increasing acknowledgment of the broader economic and social benefits that vaccinations confer. This recognition is beginning to shape the way vaccine programs are designed and evaluated, highlighting the potential for vaccines to offer greater societal benefits and encouraging their more widespread adoption.

Despite these advantages, significant challenges remain in ensuring universal vaccine access, particularly for children and vulnerable populations in areas that are geographically, politically, or culturally hard to reach. Overcoming these barriers requires a sustained commitment from all levels of governance—international, national, and local—as well as from individuals dedicated to public health advancement. Only through continuous effort and collaboration can the full potential of vaccinations be realized, enabling a healthier, more stable, and economically secure global society.

Funding
This article was not supported by any funding from public, commercial, or not-for-profit sectors.

Conflict of Interest/ Disclosures
The authors have disclosed that there are no potential conflicts of interest concerning the research, authorship, and/or publication of this article.

References

Artenstein, A. W. (2021). A half-century of meningococcal vaccines. *Vaccine*, *39*(17), 2475-2478.

Besnier, E. (2022). Women's political empowerment and child health in the sustainable development era: A global empirical analysis (1990–2016). *Global Public Health*, *18*(1), 1849348.

Brazier, J., Ratcliffe, J., Saloman, J., & Tsuchiya, A. (2017). *Measuring and valuing health benefits for economic evaluation*. OXFORD university press.

Chen, C. W., Saubi, N., & Joseph-Munné, J. (2022). Chimeric Human Papillomavirus-16 Virus-like Particles Presenting HIV-1 P18I10 Peptide: Expression, Purification, Bio-Physical Properties and Immunogenicity in BALB/c Mice. *International Journal of Molecular Sciences*, *24*(9), 8060.

Cochi, S. L., Freeman, A., Guirguis, S., Jafari, H., & Aylward, B. (2014). Global polio eradication initiative: lessons learned and legacy. *The Journal of infectious diseases*, *210*(suppl_1), S540-S546.

Das, M. K., Arora, N. K., Dalpath, S. K., Kumar, S., Kumar, A. P., Khanna, A., ... & Singh, B. (2021). Improving quality of care for pregnancy, perinatal and newborn care at district and sub-district public health facilities in three districts of Haryana, India: An Implementation study. *Plos one*, *16*(7), e0254781.

Doku, D. T., Bhutta, Z. A., & Neupane, S. (2020). Associations of women's empowerment with neonatal, infant and under-5 mortality in low-and/middle-income countries: meta-analysis of individual participant data from 59 countries. *BMJ Global Health*, *5*(1), e001558.

Drigas, A., & Mitsea, E. (2020). The 8 pillars of metacognition. *International Journal of Emerging Technologies in Learning (iJET)*, *15*(21), 162-178.

Fernandez, K. (2022). *Finance and Investing for the Long Run: Investing for Young Adults to Make the Most of Their Money*. Abiprod Pty Ltd.

Gonzalez, J. P., & Macgregor-Skinner, G. (2022). Dangerous Viral Pathogens of Animal Origin: Risk and Biosecurity: Zoonotic Select Agents. In *Zoonoses: Infections Affecting Humans and Animals* (pp. 1563-1611). Cham: Springer International Publishing.

Graham, B. S. (2013). Advances in antiviral vaccine development. *Immunological reviews*, *255*(1), 230-242.

Kraan, H., van Herpen, P., Kersten, G., & Amorij, J. P. (2014). Development of thermostable lyophilized inactivated polio vaccine. *Pharmaceutical research*, *31*, 2618-2629.

Lange, C., Aaby, P., Behr, M. A., Donald, P. R., Kaufmann, S. H., Netea, M. G., & Mandalakas, A. M. (2022). 100 years of Mycobacterium bovis bacille Calmette-Guérin. *The Lancet Infectious Diseases*, *22*(1), e2-e12.

Li, X., Mukandavire, C., Cucunubá, Z. M., Abbas, K., Clapham, H. E., Jit, M., ... & Tini Garske (Vaccine Impact Modelling Consortium). (2019). Estimating the health impact of vaccination against 10 pathogens in 98 low and middle income countries from 2000 to 2030. *MedRxiv*, 19004358.

Lindstrand, A., Cherian, T., Chang-Blanc, D., Feikin, D., & O'Brien, K. L. (2021). The world of immunization: achievements, challenges, and strategic vision for the next decade. *The Journal of Infectious Diseases*, *224*(Supplement_4), S452-S467.

Little, M. (2021). Life-Saving Antibodies: History of Immunization. In *Antibodies for Treating Cancer: Basics, Development, and Applications* (pp. 1-9). Cham: Springer International Publishing.

Pagliusi, S., Che, Y., & Dong, S. (2019). The art of partnerships for vaccines. *Vaccine*, *37*(40), 5909-5919.

Rodrigues, C. M., & Plotkin, S. A. (2020). Impact of vaccines; health, economic and social perspectives. *Frontiers in microbiology*, *11*, 1526.

Santoro, A., Bientinesi, E., & Monti, D. (2021). Immunosenescence and inflammaging in the aging process: age-related diseases or longevity?. *Ageing Research Reviews*, *71*, 101422.

Seidu, A. A., Ahinkorah, B. O., Ameyaw, E. K., Budu, E., & Yaya, S. (2022). Women empowerment indicators and uptake of child health services in sub-Saharan Africa: a multilevel analysis using cross-sectional data from 26 countries. *Journal of Public Health*, *44*(4), 740-752.

Senti, S., Habicht, M. E., Rayo, E., Eppenberger, P. E., Rühli, F. J., & Galassi, F. M. (2018). Egyptian canopic jars at the crossroad of medicine and archaeology: Overview of 100 years of research and future scientific expectations. *Pathobiology*, *85*(5-6), 267-275.

Upreti, G. (2023). Autopoiesis, Organizational Complexity, and Ecosystem Health. In *Ecosociocentrism: The Earth First Paradigm for Sustainable Living* (pp. 91-110). Cham: Springer Nature Switzerland.

Uwizihiwe, J. P., & Bock, H. (2015). 40th anniversary of introduction of Expanded Immunization Program (EPI): a literature review of introduction of new vaccines for routine childhood immunization in sub-Saharan Africa. *Int J Vaccines Vaccin*, *1*(1), 00004.

Vollset, S. E., Goren, E., Yuan, C. W., Cao, J., Smith, A. E., Hsiao, T., ... & Murray, C. J. (2020). Fertility, mortality, migration, and population scenarios for 195 countries and territories from 2017 to 2100: a forecasting analysis for the Global Burden of Disease Study. *The Lancet*, *396*(10258), 1285-1306.

World Health Organization. (2018). *2018 assessment report of the Global Vaccine Action Plan: strategic advisory group of experts on immunization* (No. WHO/IVB/18.11). World Health Organization.

Yezli, S., Saeed, A. A. B., Assiri, A. M., Alhakeem, R. F., Yunus, M. A., Turkistani, A. M., ... & Alotaibi, B. M. (2016). Prevention of meningococcal disease during the Hajj and Umrah mass gatherings: past and current measures and future prospects. *International Journal of Infectious Diseases*, *47*, 71-78.

Younger, D. S. (2016). Vaccination: Epidemiological Review. *World Journal of Neuroscience*, *7*(1), 55-65.

Zaffran, M., McGovern, M., Hossaini, R., Martin, R., & Wenger, J. (2018). The polio endgame: securing a world free of all polioviruses. *The Lancet*, *391*(10115), 11-13.